Avlayah (tividenofusp alfa-eknm) Coverage Criteria
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0302 alerts
Get alerted when Policy CC-0302 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity review and prior authorization for Avlayah in pediatric individuals with Mucopolysaccharidosis II (Hunter syndrome), including initial treatment, continuation therapy, quantity limits, and applicable billing codes. Coverage is limited to neurologic manifestations before advanced neurologic impairment.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.